GlaxoSmithKline Partners with CureVac to Develop mRNA-based Vaccines
By Pratika Pahwa & Michelle Liu
Pharma Deals Review: Vol 2020 Issue 7 (Table of Contents)
Published: 29 Jul-2020
DOI: 10.3833/pdr.v2020.i7.2550 ISSN: 1756-7874
Section: Research & Development
Fulltext:
Abstract
Expanding its footprint in vaccine business, GlaxoSmithKline (GSK) has agreed to partner with CureVac to develop and commercialise up to five mRNA-based vaccines and monoclonal antibodies targeting infectious diseases...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS